Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84).

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Immunochemotherapy with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has become standard of care for patients with diffuse large B-cell lymphoma (DLBCL). This randomized trial assessed whether rituximab intensification during the first 4 cycles of R-CHOP could improve the outcome of these patients compared with standard R-CHOP.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Clin Oncol

Title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Publisher: American Society of Clinical Oncology (ASCO)

ISSN (Electronic): 1527-7755

ISSN (Print): 0732-183X

Publication date (Electronic): October 10 2020

Volume: 38

Issue: 29

Affiliations

[1 ] Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

[2 ] Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.

[3 ] Haemato Oncology Foundation for Adults in the Netherlands (HOVON) Data Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

[4 ] Aarhus University Hospital, Aarhus, Denmark.

[5 ] St Antonius Hospital, Nieuwegein, the Netherlands.

[6 ] Albert Schweitzer Hospital, Dordrecht, the Netherlands.

[7 ] Meander MC, Amersfoort, the Netherlands.

[8 ] Amphia Hospital, Breda, the Netherlands.

[9 ] Haga Teaching Hospital, The Hague, the Netherlands.

[10 ] Jeroen Bosch Hospital, 's Hertogenbosch, the Netherlands.

[11 ] University Hospitals Leuven, Leuven, Belgium.

[12 ] Medical Center Leeuwarden, Leeuwarden, the Netherlands.

[13 ] Admiraal de Ruijter Hospital, Goes, the Netherlands.

[14 ] University Medical Center Groningen, Groningen, the Netherlands.

[15 ] Bravis Hospital, Roosendaal, the Netherlands.

[16 ] Canisius Wilhelmina Hospital, Nijmegen, the Netherlands.

[17 ] Zuyderland Medical Center, Heerlen, the Netherlands.

[18 ] Odense University Hospital, Odense, Denmark.

[19 ] Maastricht University MC, Maastricht, the Netherlands.

[20 ] Maasstad Hospital, Rotterdam, the Netherlands.

[21 ] Tergooi Hospitals, Hilversum, the Netherlands.

[22 ] Isala Hospital, Zwolle, the Netherlands.

[23 ] Spaarne Gasthuis, Hoofddorp, the Netherlands.

[24 ] Amsterdam UMC, AMC, Amsterdam, the Netherlands.

[25 ] Maxima Medical Center, Eindhoven, the Netherlands.

[26 ] Reinier de Graaf Hospital, Delft, the Netherlands.

[27 ] Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

[28 ] UMC Utrecht, Utrecht, the Netherlands.

[29 ] Radboud UMC, Nijmegen, the Netherlands.

[30 ] HOVON Pathology Facility and Biobank, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Article

DOI: 10.1200/JCO.19.03418

PubMed ID: 32730183

SO-VID: ac3bf11a-931a-4bae-86b1-98e8228c8e62

History

Data availability:

Comments

Comment on this article

scite_

Cited by 26

See all cited by